Hepatobiliary dysfunction during total parenteral nutrition is caused by infusate, not the route of administration.
Cholestatic jaundice is the major complication of total parenteral nutrition (TPN). Both the intravenous (IV) route of nutrition and the enteral fast have been implicated as causes of TPN-associated cholestasis (TPN-AC). The purpose of this study was to determine whether TPN-AC is caused by the TPN solution itself or the IV route of administration and enteral fast. Prepubescent rabbits (n = 24) were divided into four groups: CONTROL, fed standard lab chow; TPN, received a standard hyperalimentation solution of dextrose, Aminosyn, and lipids via the jugular vein; ENT, received the same hyperalimentation solution via a duodenostomy tube; and OSM, received a polymeric formula (Osmolite) via a duodenostomy tube. After 14 days on these diets, we measured bile flow, bile acid excretion, sulfobromophthalein (BSP) excretion, plasma amino acid profile, serum liver enzymes, and liver histology. Statistical analysis was by analysis of variance. Hyperalimentation solution significantly depressed hepatobiliary function, whether it was given IV or by gut. Bile flow in both the TPN (36.4 microL/kg/min) and ENT (46.2) groups was significantly less than CONTROL (84.5) or OSM (62.9). Hepatic secretory function, measured by excretion of the cholephilic dye BSP, was depressed in both TPN and ENT (57% and 55% of IV dose excreted in bile over 60 minutes, respectively) compared with CONTROL (84%) or OSM (71%). Serum liver enzymes were normal in all groups. Histological injury similar to TPN-AC in humans (portal inflammation and hepatocyte degeneration) was seen in both groups receiving the hyperalimentation solution.(ABSTRACT TRUNCATED AT 250 WORDS)
Moss
R L
RL
Children's Memorial Hospital, Chicago, IL 60614.
Das
J B
JB
Ansari
G
G
Raffensperger
J G
JG
D000596:Amino Acids / Q000009:adverse effects* / Q000097:blood; D000818:Animals; D002241:Carbohydrates / Q000008:administration & dosage / Q000009:adverse effects*; D002364:Caseins / Q000008:administration & dosage / Q000009:adverse effects*; D002779:Cholestasis / Q000097:blood / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D004573:Electrolytes; D004750:Enteral Nutrition; D005947:Glucose / Q000009:adverse effects*; D007263:Infusions, Parenteral; D008055:Lipids / Q000008:administration & dosage / Q000009:adverse effects*; D008954:Models, Biological; D057947:Parenteral Nutrition Solutions; D010289:Parenteral Nutrition, Total; D014674:Plant Proteins, Dietary / Q000008:administration & dosage / Q000009:adverse effects*; D011817:Rabbits; D012996:Solutions
D000596:Amino Acids; D002241:Carbohydrates; D002364:Caseins; D004573:Electrolytes; D008055:Lipids; D057947:Parenteral Nutrition Solutions; D014674:Plant Proteins, Dietary; D012996:Solutions; C545824:amino-acid, glucose, and electrolyte solution; C080652:Osmolite; D005947:Glucose